AHPA Statement on oleandrin and Nerium oleander

AHPA Alerts

AHPA Alerts

AHPA keeps members and the industry informed of recent news and developments that impact the trade through email alerts. Subscribe to news as it happens or a weekly summary of all alerts.

Subscribe >>

View recent alerts:

Subscribe to AHPA Updates to stay informed about the latest AHPA news and resources.

Recent News

AHPA Statement on oleandrin and Nerium oleander

AHPA strongly discourages sales or marketing of dietary supplements that contain any part of the oleander plant

Published: Tuesday, August 18, 2020

Over the last few days, the potential use of oleandrin for treatment of COVID-19 has received significant media attention.

The American Herbal Products Association (AHPA) strongly discourages sales or marketing of dietary supplements that contain any part of the oleander plant (Nerium oleander) or its constituent, oleandrin. AHPA also urges physical and online retailers to refrain from offering any such products for sale, and AHPA cautions consumers to avoid oral consumption of oleander or oleandrin.

Oleandrin is a cardiac glycoside found in the oleander plant. Oleander is a highly toxic plant, and death has been associated with oral ingestion of even small amounts of oleander leaf.

Of particular interest to dietary supplement marketers, a new dietary ingredient (NDI) notification was submitted to the Food and Drug Administration (FDA) for an oleander extract in 1998. FDA responded to this notification by noting, in part, “All parts of the oleander plant are poisonous to man and animals … [due to] the cardiac glycosides in oleander … [including] oleandrin….” In reviewing the NDI notification records, AHPA notes it is exceedingly rare for the agency to essentially reject a notification due to known safety concerns. Indeed, among the responses to the more than 1,000 NDI notifications released by FDA to date, AHPA identified only seven expressing known safety concerns in this manner.

AHPA advises that anyone who believes they may have contracted COVID-19 should contact a healthcare professional immediately. The Centers for Disease Control and Prevention has more information on the novel coronavirus and the proper actions to take if you suspect you are ill.

Print

2020 Annual Fund Sponsors

   

AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.